Id1 and Sonic Hedgehog Mediate Cell Cycle Reentry and Apoptosis Induced by Amyloid Beta-Peptide in Post-mitotic Cortical Neurons
Overview
Neurology
Affiliations
Amyloid beta-peptide (Aβ), the neurotoxic component of senile plaques in Alzheimer's disease (AD) brains, is known to trigger cell cycle reentry in post-mitotic neurons followed by apoptosis. However, the underlying mechanisms remain unclear. Recently, we have reported that Aβs stimulate the expression of inhibitor of differentiation-1 (Id1) to induce sonic hedgehog (SHH) (Hung et al., Mol Neurobiol 53(2):793-809, 2016), and both are mitogens capable of triggering cell cycle progression. In this work, we tested the hypothesis that Aβ-induced Id1 and SHH contribute to cell cycle reentry leading to apoptosis in neurons. We found that Aβ triggered cell cycle progression in the post-mitotic neurons, as indicated by the increased expression of two G1-phase markers including cyclin D1 and phosphorylated retinoblastoma protein (pRb), two G2-phase markers such as proliferating cell nuclear antigen (PCNA) and incorporation of 5-bromo-2'-deoxyuridine (BrdU) into newly synthesized DNA, as well as the mitotic marker histone H3 phosphorylated at Ser-10. As expected, Aβ also enhanced caspase-3 cleavage in the cortical neurons. Id1 siRNA, the neutralization antibody against SHH (SHH-Ab), and the cyclin-dependent kinase (CDK)-4/6 inhibitor PD0332991 all attenuated, in part or in full, the Aβ-induced expression of these cell cycle markers. Indeed, exogenous recombinant Id1 protein and the biologically active N-terminal fragment of SHH (SHH-N) were both sufficient to enhance the expression of cell cycle markers independent of Aβ. Taken together, our results revealed the critical roles of Id1 and SHH mediating Aβ-dependent cell cycle reentry and subsequently caspase-dependent apoptosis in the fully differentiated post-mitotic neurons, at least in vitro.
Potential Roles of Hypoxia-Inducible Factor-1 in Alzheimer's Disease: Beneficial or Detrimental?.
Lin T, Huang C, Lin K, Hsieh Y, Chen S, Lin Y Antioxidants (Basel). 2024; 13(11).
PMID: 39594520 PMC: 11591038. DOI: 10.3390/antiox13111378.
Wu M, Chao A, Hsieh Y, Lien Y, Lin Y, Yang D Int J Mol Sci. 2024; 25(17).
PMID: 39273571 PMC: 11395613. DOI: 10.3390/ijms25179626.
Hou B, Wu M, Hsu H, Lin Y, Yang D Int J Mol Sci. 2024; 25(13).
PMID: 39000427 PMC: 11242684. DOI: 10.3390/ijms25137316.
Taylor O, Patel S, Hawthorn E, El-Hodiri H, Fischer A Glia. 2024; 72(7):1236-1258.
PMID: 38515287 PMC: 11334223. DOI: 10.1002/glia.24523.
FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders.
Lui A, Vanleuven J, Perekopskiy D, Liu D, Xu D, Alzayat O Pharmaceuticals (Basel). 2022; 15(12).
PMID: 36558997 PMC: 9784968. DOI: 10.3390/ph15121546.